Agios early-stage AML drug shines
Agios Pharmaceuticals’ AG-120, a first-in-class inhibitor of the IDH1 mutant protein has shown remarkable efficacy in an early-stage trial in patients with acute myeloid leukaemia. - News - PharmaTimes
by Neil Canavan
https://www.pharmatimes.com/news/agios_early-stage_aml_drug_shines_1002868